EUVIMEDEUVIMED entdecken
Crossref

Diagnostic, prognostic, and therapeutic biomarkers in neuroendocrine tumors

Hayley R. Vaughn

Iowa Research Online (The University of Iowa) · 12.04.2024

DOI: 10.25820/etd.007406 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Iowa Research Online (The University of Iowa), erschienen am 12.04.2024. Verfasst von Hayley R. Vaughn.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroendocrine tumors (NETs) are a heterogenous group of mainly epithelial neuroendocrine neoplasms with high metastatic potential. Up to 60% of patients have advanced metastatic liver disease at the time of diagnosis. Twelve to fifty percent of primary NETs in the abdomen are regularly missed due to small tumor size, body habitus, and abdominal gases. Of these, 50% originate in the pancreas (pNETs) and small bowel (sbNETs). Often located in close proximity, they are difficult to differentiate because of similar signs and symptoms, including abdominal pain, nausea, poor appetite, weight loss, and diarrhea. However, it is particularly important to differentiate between pNETs and sbNETs due to different treatment options and protocols.

Schlagwörter

neuroendocrine tumorsbiomarkersdiagnostic biomarkersprognostic factorstherapeutic biomarkerspancreatic neuroendocrine tumorssmall bowel neuroendocrine tumorsliver metastasisdifferential diagnosismetastasis

Zitieren

APA

Vaughn, H. R. (2024). Diagnostic, prognostic, and therapeutic biomarkers in neuroendocrine tumors. Iowa Research Online (The University of Iowa). https://doi.org/10.25820/etd.007406

Vancouver

Vaughn HR. Diagnostic, prognostic, and therapeutic biomarkers in neuroendocrine tumors. Iowa Research Online (The University of Iowa). 2024. doi:10.25820/etd.007406

BibTeX
@article{Vaughn2024,
  author = {Vaughn, Hayley R.},
  title = {Diagnostic, prognostic, and therapeutic biomarkers in neuroendocrine tumors},
  journal = {Iowa Research Online (The University of Iowa)},
  year = {2024},
  doi = {10.25820/etd.007406}
}
Kostenlos starten →